Drug for Ultra Rare Disease Comes with Ultra High Price Tag

(Bloomberg) -- Alnylam Pharmaceuticals Inc.’s Givlaari became the first drug to win U.S. approval for patients with an ultra-rare and devastating metabolic disorder. Shares jumped on the news.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.